UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN) granted inducement restricted stock units (RSUs) to 21 new employees under Nasdaq Listing Rule 5635(c)(4). These hires will support commercialization of JELMYTO and ZUSDURI and pipeline development. Up to 102,700 ordinary shares are issuable as the RSUs vest equally over three years.

News Market Reaction – URGN

-2.72%

-2.72% Session close to close

In the Jun 5 session, URGN declined 2.72%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement RSU grants covering up to 102,700 shares for 21 new employees, ...

Analysis

This announcement details inducement RSU grants covering up to 102,700 shares for 21 new employees, vesting over three years under the 2019 Inducement Plan. It expands equity-based compensation as UroGen commercializes JELMYTO and ZUSDURI and advances its pipeline. In context of recent strong clinical data and a patent settlement, investors may watch how overall equity issuance and insider activity evolve relative to revenue growth and operating expenses.

Key Figures

New employees: 21 RSU share maximum: 102,700 ordinary shares Vesting period: 3 years

3 metrics

New employees 21 Employees receiving inducement RSU grants

RSU share maximum 102,700 ordinary shares Shares issuable upon RSU vesting and settlement

Vesting period 3 years RSUs vest in three equal annual installments

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Patent settlement	Positive	-1.8%	Settlement and license agreement with Teva resolving JELMYTO patent litigation.
Jun 01	Conference appearance	Neutral	-1.8%	Announcement of presentation at Goldman Sachs Global Healthcare Conference.
May 15	Phase 3 data	Positive	-3.0%	UGN-103 showed 94.5% six-month DOR in Phase 3 UTOPIA trial.
May 13	Clinical update	Positive	+3.8%	ENVISION trial update showed 64.5% 36-month DOR for ZUSDURI.
May 07	Investor conferences	Positive	+1.3%	Participation in multiple May investor conferences to engage shareholders.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been fundamentally positive, but price reactions have been mixed, with several constructive clinical and legal updates met by negative or muted moves.

Recent Company History

Over the last month, UroGen has reported several notable milestones. An 8-K and related press release on June 2 detailed a settlement and license with Teva over JELMYTO generics. In mid-May, Phase 3 data for ZUSDURI and UGN-103 showed strong durability of response, supporting the bladder cancer franchise. Conference participation in May and June signaled active investor outreach. Against this backdrop, today’s inducement RSUs expand employee ownership as the company commercializes JELMYTO and ZUSDURI and advances its pipeline.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), pyelocalyceal, intravesical

4 terms

restricted stock units financial

"announced the grants of inducement restricted stock units (“RSUs”) to 21 new employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

pyelocalyceal medical

"JELMYTO (mitomycin) for pyelocalyceal solution and ZUSDURITM"

Pyelocalyceal describes the parts of the kidney that collect and channel urine — the renal pelvis (a central funnel) and the calyces (small cups that feed into it). For investors, it matters when products, tests, or diseases target this area because clinical outcomes, regulatory approvals, and market demand for treatments or diagnostic tools can hinge on conditions like obstruction, infection, or tumors in these structures. Think of it as the plumbing junction inside a kidney where blockages or damage can drive medical and commercial activity.

intravesical medical

"ZUSDURITM (mitomycin) for intravesical solution, UroGen’s only approved products"

Intravesical describes a medical treatment or procedure where a drug or therapy is placed directly into the bladder through a catheter rather than taken by mouth or injected into the bloodstream. For investors, it signals a focused delivery method that can increase local effectiveness and reduce whole‑body side effects, often affecting a product’s clinical value, patient convenience, regulatory path, and market niche — like watering a plant at its roots instead of spraying its leaves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO^® (mitomycin) for pyelocalyceal solution and ZUSDURI^TM (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.

Up to 102,700 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X, @UroGenPharma.

JELMYTO^®, RTGel^®, ZUSDURI™ and UroGen^® are registered trademarks of UroGen Pharma Ltd.

INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3566 Ext. 1083

FAQ

What did UroGen Pharma (URGN) announce on June 5, 2026 about inducement grants?

UroGen Pharma announced inducement grants of restricted stock units (RSUs) to 21 new employees. According to UroGen, these RSUs are tied to their employment and are intended to support commercialization of JELMYTO, ZUSDURI, and continued development of the company’s pipeline programs.

How many shares are covered by UroGen Pharma’s new inducement RSU grants for URGN?

The inducement RSU grants cover up to 102,700 ordinary shares of UroGen Pharma. According to UroGen, these shares will become issuable upon vesting and settlement of the RSUs, aligning employee incentives with the company’s long-term commercialization and development goals.

What is the vesting schedule for UroGen Pharma’s June 2026 inducement RSUs for URGN employees?

The inducement RSUs vest in three equal annual installments over three years. According to UroGen, one-third of the underlying shares vests each year on the anniversary of the vesting date, subject to the employee’s continued service relationship with the company.

Why did UroGen Pharma grant inducement RSUs under Nasdaq Listing Rule 5635(c)(4)?

UroGen Pharma granted inducement RSUs as a material incentive for new employees to join the company. According to UroGen, the awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are governed by the company’s 2019 Inducement Plan and related agreements.

How will UroGen Pharma’s new inducement RSUs support JELMYTO and ZUSDURI commercialization?

The new employees receiving inducement RSUs will support commercialization of JELMYTO and ZUSDURI. According to UroGen, these team members will also contribute to advancing its broader pipeline, aligning equity incentives with execution of current product strategies and future development efforts.